• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Maleic acid salt of a silodosin intermediate. The present invention relates to a salt of formula (I), its preparation process and its use in the preparation of silodosin. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2607639A1
    申请号:ES201531398
    申请日:2015-09-30
    公开日:2017-04-03
    发明作者:Xavier Vila Tusell；José Luis DEL RÍO PERICACHO
    申请人:Urquima SA；
    IPC主号:
    专利说明:

    Maleic acid salt of a silodosin intermediate
    5 Field of the invention
    The present invention relates to a maleic acid salt of 3- {7 -cyano5- (2R) -2 - ({2 - (2 - (2, 2-2-triflu oroethoxy) phenoxy] eti I) amin benzoate o) propyl] -2,3-di hydro-1 H-in d 01-1-iI) propyl of formula (1)
    or or
    HO- {J-OH
    (one),
    which is a key precursor in the manufacture of silodosin, with the process of preparing said salt and with its use in the preparation of silodosin.
    15 Background of the invention
    Silodosin, whose chemical structure is represented by formula (V) below
    Or NH,
    ~ OH
    N
    (SAW,
    20 is an antagonist of the o-adrenergic receptors, selective for the adrenergic receptors to A that are located primarily in the prostate, base and neck of the bladder, capsule and prostatic urethra. The blockage of these receptors causes smooth muscle relaxation that reduces resistance in the bladder outlet region without affecting the detrusor smooth muscle contractility, improving storage symptoms
    25 (irritative) and emptying (obstructive) associated with benign prostatic hyperplasia. The affinity of silodosin for 0 1B adrenergic receptors located in the system
    Cardiovascular is substantially smaller. Due to these characteristics, silodosin is used in the treatment of the signs and symptoms of benign prostatic hyperplasia.
    Silodosin, its preparation procedure and its therapeutic use are described in the
    5 document EP O 600 675 A1. The procedures described in this document involve thealkylation of primary amine derivatives, either with a halogenated derivative or withan activated alcohol, to give a secondary amine intermediate and its subsequentSilodosin transformation. To purify intermediate and final products in thepreparation of silodosin, EP O 600 675 A1 describes the use of chromatography
    10 of column, which supposes an inconvenience for the development of the procedure at industrial level.
    Silodosin production procedures have been described that avoid the use of purification steps by column chromatography. In this regard, EP 1 806 15 340 A1 describes the formation of an oxalate salt of the compound of formula (11) (intermediate in the synthesis of silodosin)
    or
    (eleven )
    EP 1 806340 A1 describes obtaining the compound of formula (11) by an alkylation reaction of the amine of formula (111)
    or
    (111)
    with a compound of formula (IV)
    (IV), where GS is a leaving group; and subsequent conversion of the compound of formula (11) obtained in silodosin. The process described in EP 1 806 340 A 1 comprises the formation of the oxalate salt of the compound of formula (11), which is an insulating solid by crystallization, and therefore separable from impurities that remain in solution in the medium of reaction.
    WO 2012/147019 A1 describes a similar process comprising the formation of the tartrate salt of the compound of formula (11), also in solid form.
    There is a need to have alternative procedures for the synthesis of silodosin that allow obtaining said product on an industrial scale facilitating the purification and manipulation steps of the process.
    Summary of the invention
    The inventors have investigated alternative procedures for the synthesis of silodosin that allow obtaining said product on an industrial scale by facilitating the purification and handling steps of the process, in particular, alternative purification procedures of the compound of formula (11) (key intermediate in the production of silodosin). In this regard, the inventors have attempted to purify the compound of formula (11) by forming the salts of maleate, glycolate, citrate, succinate, fumarate, hydrochloride, hydrobromide, sulfate, phosphate, acetate or methanesulfonate of the amine of formula ( eleven). Surprisingly, as shown in example 1 of the present application, among all the acids tested, maleic acid is the only one that yields a salt of the compound of formula (11) in solid form and, therefore, separable by filtration. and suitable for the separation of impurities, in particular of those impurities that remain in solution in the reaction medium at this stage of formation of said intermediate (11), and therefore advantageous for the production of silodosin on an industrial scale. In addition, the formation of a solid intermediate has advantages in terms of handling the intermediate in the production of silodosin.
    Therefore, in a first aspect, the present invention relates to the maleic acid salt of formula (1)
    o o
    H0-U-0H
    (one).
    In a second aspect the invention relates to a process for the preparation 5 of the maleic acid salt of formula (1)
    O o
    H0-U-0H CN O
    - C (~~
    I
    h O ............ CF
    (one ) which includes:
    a) treat the compound of formula (11)
    CN
    - CCO ~ N
    I
    h O ............ CF H
    10 3
    (eleven )
    with maleic acid; Y
    b) isolate the salt of formula (1).
    In a third aspect, the invention relates to a method of preparing silodosin of formula (V)
    or NH,
    (V)which comprises hydrolyzing the salt of formula (1) for the silodosin of formula (V).
    5 Brief description of the figures Figure 1 shows the powder X-ray diffractogram of the salt polymorph of formula
    (1) obtained in example 2.
    10 Figure 2 shows the powder X-ray diffractogram of the silodosin gamma polymorph obtained in Examples 3 and 4.
    Figure 3 shows the powder X-ray diffractogram of the silodosin beta polymorph obtained in Example 5
    DETAILED DESCRIPTION OF THE INVENTION Salt of formula (1) In a first aspect, the invention relates to the salt of maleic acid of formula (I)
    O o
    (one)
    In said salt of formula (1), maleic acid and 3- {7 -cyano-5 - [(2R) -2- ({2- [225 (2,2,2-trifluoroethoxy) phenoxy] ethyl benzoate } amino) propyl] -2,3-dihydro-1 H-indol-1-yl} propyl are in a molar ratio of about 1: 1, that is, that is, per mole of 3-benzoate
    {7 -cyano-5 - [(2R) -2- ({2- [2- (2,2,2-trifluoroethoxy) phenoxy] ethyl} amino) propyl] -2,3-dihydro-1 H-indole- 1 il} propyl present in the salt is one mole of maleic acid.
    Said salt may also be in the form of solvate, in particular hydrate or alcoholate, such as isopropanolate.
    The term Usolvate "according to this invention should be understood as meaning any form of the salt of formula (1) which has another molecule (generally a polar solvent) attached through a non-covalent bond. Solvates especially include hydrates and alcoholates, for example isopropanolate.
    In a preferred embodiment, the present invention relates to a polymorph of compound of formula (1) characterized in that its powder X-ray diffractogram (registered with a copper X-ray source) has peaks at 11, 9, 14 , 6, 15.4, 17.1, 18.4, 21.0, 23.4 and 23.9 '29 ± 0.2 '29.
    The expression "± 0.2 ° 28" refers to the measurement error and means that the value indicated for each of the peaks can be in the range defined by the indicated value -0.2 ° 28 and the indicated value + 0.2 ° 28.
    In a preferred embodiment, the polymorph of the compound of formula (1) is characterized in that its powder X-ray diffractogram (registered with a copper X-ray source) also has peaks at 11, 7, 14,4, 16 , 7 and 18.9 ° 28 ± 0.2 ° 28. More preferably, the powder X-ray diffractogram (registered with a copper X-ray source) of said polymorph also has peaks at 19.0, 19.8, 22.2, 24.4 and 25.1 '29 ± 0.2 '29. More preferably, the powder X-ray diffractogram (registered with a copper X-ray source) of said polymorph also has peaks at 3.0, 9.2, 9.4, 12, 3, 14.9, 17.9, 20.2, 24.7, 25.9, 29.0, 29.3 and 30.1 ° 28 ± 0.2 ° 28. In a particular embodiment, the polymorph is characterized by powder X-ray diffractogram (registered with a copper X-ray source) presenting the peaks, and preferably also the relative intensities, shown in Table 1.
    Table 1. X-ray powder diffractogram of the compound of formula (1)Position (° 28) Relative intensity (%)
    Position (° 28) Relative intensity (%) 3.0 6.1
    7.2 3.61
    Position ("2e) Relative Intensity (%)
    9.2 6.81
    9.4 7.52
    9.9 1.5
    11, 7 17.82
    11, 9 31, 48
    12.3 8.08
    14.4 16.73
    14.6 40.83
    14.9 8.79
    15.4 37.41
    16.7 16.05
    17.1 34.63
    17.9 8.26
    18.4 20.63
    18.9 19.06
    19.0 12.14
    19.4 4.81
    19.8 14.53
    20.2 6.96
    21.0 27.11
    Position (° 28) Relative Intensity (%)
    22.2 9.63
    22.7 5.9
    22.8 5.87
    23.4 100
    23.9 29.07
    24.4 12.61
    24.7 6.05
    25.1 9.86
    25.9 6.37
    26.8 5.22
    27.6 2.97
    28.3 1.87
    28.7 4.79
    29.0 7.72
    29.3 6.45
    30.1 7.12
    30.7 2.22
    31, 4 4.37
    31, 9 3.77
    In a particular embodiment, said polymorph of the compound of formula (1) has a powder X-ray diffractogram (registered with a copper X-ray source) substantially like that shown in Figure 1.
    Said polymorph can be obtained by recrystallization of the compound of formula (1) from isopropanol.
    Here the terms "compound of formula (Ir," salt of formula (1) ", usal 10 of maleic acid of formula (1)" are used interchangeably and refer to the salt of
    3- (7-cyano-5 - [(2R) -2 - ({2- [2- (2,2,2
    triflu oroethoxy) fe noxi] ethyl} a m ino) p ropi 1] -2> 3-dihydro-1 H-i n d ol-1-i I} propyl.
    Salt preparation process of formula (1)
    In a second aspect, the invention relates to a process for the preparationof the maleic acid salt of formula (1) defined above, comprising:a) treat the compound of formula (11)
    (eleven )
    with maleic acid; and 10 b) isolating the salt from the maleic acid of formula (1).
    Step a) is preferably carried out in a solvent selected from the group consisting of methanol, ethanol, n-propanol, sopropanol, tere-butanol, n-butanol and mixtures thereof, preferably isopropanol.
    Said solvent may optionally also contain, as other minor components present in no more than 20% v / v, preferably in no more than 15% v / v, more preferably in no more than 10% vlv, more preferably in no more than 5% v / v, even more preferably in no more than 1% v / v. These minority components
    20 may be, among others, water and aprotic polar solvents.
    The term "aprotic polar solvent" refers to a polar solvent that does not have hydrogen atoms attached to an electronegative atom and capable of forming hydrogen bonds such as hydrogen atoms of the OH and NH Y groups whose dielectric constant 25 is of at least 3, said dielectric constant being the ratio between the electrical capacity of a capacitor full of solvent and the electrical capacity of the capacitor at 20-25 oC. The dielectric constant values of various solvents are described, for example, in "Vogel's Textbook of Practical Organic Chemistry", 58 edition, Appendix. Examples of aprotic polar solvents are acetonitrile, tetrahydrofuran, ethyl acetate, butyl acetate,
    Acetone, methyl isobutyl ketone, ethyl methyl ketone, dimethylformamide, dimethylsulfoxide, dichloromethane, nitromethane and propylene carbonate, among others.
    In particular, the aprotic polar solvent, present as a minor component of the solvent used in step a) is the aprotic polar solvent used in the preparation of the compound of formula (11), preferably acetonitrile.
    The volume of solvent suitable for step a) can be easily determined by the person skilled in the art and will depend on the particular solvent used. Preferably between 20 L and 60 L of solvent are used per kg of maleic acid, more preferably between 30 L and 50 L of solvent per kg of maleic acid, even more preferably between
    10 35 L and 45 L per kg of maleic acid, most preferably about 40 L per kg of maleic acid.
    The treatment of step a) is preferably carried out with stirring of the mixture of compound of formula (11), maleic acid and solvent until dissolved, more preferably 15 at a temperature between 40 ° C and 60 ° C, even more preferably between 45 ° C and 55 oC, most preferably about 50 oC.
    Once said mixture has dissolved, it is preferably cooled to a temperature not exceeding 25 oC, more preferably between 15 oC and 25 oC, more preferably between 20
    20 oC and 25 oC, even more preferably about 20 oC, maintaining stirring, preferably between 10 h and 50 h, more preferably between 10 h and 40 h, more preferably between 10 h and 30 h, more preferably between 10 h and 20 h, more preferably at least 15 h.
    In a particular embodiment, the maleic acid and the compound of formula (JI) of step a) are in a molar ratio of between 1.5: 1 and 1: 1, preferably between 1.2: 1 and 1: 1, more preferably between 1.1: 1 and 1: 1, more preferably about 1.1: 1.
    In the context of the present invention, it should be considered that the ends of the ranges 30 mentioned are part of said ranges unless otherwise indicated.
    The synthesis of the compound of formula (11) has been previously described, for example in EP 1806340 A1 and WQ 2021/147019 A1, which are incorporated by reference in this regard.
    In a particular embodiment, the compound of formula (11) of step a) is obtained by treating the compound of formula (111) or a salt thereof
    in
    or
    (111)5 with a compound of formula (IV)
    wherein GS is a leaving group, in an aprotic polar solvent, and in the presence of a base, to give the compound of 10 formmu (11).
    The term "leaving group" refers to the fragment of the molecule that is displaced by the amino group of the compound of formula (111) to form the compound (11). The leaving groups are known to those skilled in the art. Examples of groups Suitable projections for the compound of formula (IV) are C, -C-alkylsulfonyloxy, such as methanesulfonyloxy (CH3-S03-); Cl -Cs haloalkylsulfonyloxy, such as trifluoromethanesulfonyloxy (CF3-SOd; arylsulfonyloxy, such as benzenesulfonyloxy (Ph-SOd , toluenesulfonyloxy "P-CH3) Ph-S03-), p-bromobenzenesulfonyloxy" p-Br) -Ph-S03-), o-nitrobenzenesulfonyloxy "o-NOz) Ph-S03-) and p-nitrobenzenesulfonyloxy" P-NOz) -Ph-S03-); halogen atom, such as chlorine 20 (CI-), bromine (Br-) and iodine (1-) Preferably the leaving group is selected from the group consisting of C1-C3 alkylsulfonyloxy, C1- C3 haloalkylsulfonyloxy, arylsulfonyloxy, and halogen atom More preferably the leaving group is selected from the group consisting in methanesulfonyloxy, trifluoromethanesulfonyloxy, toluenesulfonyloxy, chlorine, bromine and iodine. Even more preferably, the leaving group is selected from the group consisting of methanesulfonyloxy, trifluoromethanesulfonyloxy and toluenesulfonyloxy. In the realization more
    preferred the leaving group is methanesulfonyloxy.
    The term "alkyl" or "alkyl" refers to a linear hydrocarbon chain radical or
    branched consisting of carbon and hydrogen atoms, which does not contain unsaturations, 30 which has the number of carbon atoms indicated in each case (for example Cl-Cs means that it has 1 to 6 carbon atoms) and that is attached to the rest of the molecule
    through a simple link. Examples of alkyl are methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, tert-butyl, pentyl, hexyl, etc.
    5 The term "arir or" aryl "refers to an aromatic hydrocarbon radical consisting ofcarbon and hydrogen atoms containing between 6 and 18 carbon atoms and that isbound to the rest of the molecule by a single bond, such as phenyl, naflyl or anthracil,preferably phenyl. The aryl radical may be optionally substituted by one or moresubstituents (such as one, two or three substituents) independently selected from the
    10 group consisting of alkyl e l-eS (preferably alkyl e l-e3), halogen and nitro (N02).
    The term "halogen" or "halo" refers to an atom selected from F, el, Br and 1.
    The term "alkyl sulfonyloxy" refers to an alkyl group as defined.
    Previously it is linked to a sulfonyloxy group (-80d and wherein said sulfonyloxy group is linked to the rest of the molecule by a single bond. Example of alkylsulfonyloxy is methanesulfonyloxy.
    The term "haloalkylsulfonyloxy" refers to an alkylsulfonyloxy group as defined.
    20 above, which further comprises one or more (such as one, two, three, four, five or six) halogen atoms as substituents of the alkyl group. Example of haloalkylsulfonyloxy is trifluoromethanesulfonyloxy.
    The term "arylsulfonyloxy" refers to an aryl group as defined above.
    25 which is linked to a sulfonyloxy group (-803-) and wherein said sulfonyloxy group is linked to the rest of the molecule by a single bond. Examples of arylsulfonyloxy are benzenesulfonyloxy, toluenesulfonyloxy, p-bramobenzenesulfonyloxy, o-nitrabenzenesulfonyloxy and p-nitrabenzenesulfonyloxy.
    In a particular embodiment, the aprotic polar solvent used in obtaining the compound of formula (11) of step a) by treating the compound of formula
    (111) or a salt thereof with a compound of formula (IV) is selected from the group consisting of acetonitrile, tetrahydrofuran, ethyl acetate, butyl acetate, acetone, methyl isobutyl ketone, ethylmethyl ketone, dimethylformamide, dimethyl sulfoxide, dichloramethane,
    35 nitramethane and prapylene carbonate, and mixture thereof. Preferably the organic solvent used is acetonitrile.
    In a preferred embodiment, in obtaining the compound of formula (11) of step a) by treating the compound of formula (111) or a salt thereof with a compound of formula (IV), as described above. , the salt of the tartaric acid of the compound of formula (111), preferably the salt of the acid (2R, 3R) - (+) - tartaric acid is used.
    In obtaining the compound of formula (11) of step a) by treating the compound of formula (111) or a salt thereof with a compound of formula (IV) a base is used. Said base may be an inorganic base such as an alkali metal hydroxide (for example sodium hydroxide or potassium hydroxide), an alkali metal carbonate (for example sodium carbonate, potassium carbonate, cesium carbonate), or it can also be an organic base, such as a di-or tri-C 1 -C 6 alkylamine (for example triethylamine, diethylamine and diisopropylamine). In a particular embodiment the base is an inorganic base, more preferably an alkali metal carbonate, even more preferably potassium carbonate. Preferably, the base and the compound of formula
    (111) or a salt thereof is in a molar ratio of between 3: 1 and 1: 1, preferably between 2.5: 1 and 1: 1, more preferably 2: 1 and 1: 1.
    In obtaining the compound of formula (11) of step a) by treating the
    20 compound of formula (111) or a salt thereof with a compound of formula (IV), said treatment is preferably carried out with stirring at reflux temperature of the solvent. Preferably said treatment is carried out by stirring between 10 h and 50 h, more preferably between 10 h and 40 h, more preferably between 10 h and 30 h, more preferably about 24 h.
    In obtaining the compound of formula (11) of step a) by treating the compound of formula (111) or a salt thereof with a compound of formula (IV), the compound of formula (IV) and the compound of formula (11 1) or the salt thereof is in a molar ratio of between 1.5: 1, preferably between 1.2: 1.
    Once stage a) of treatment of the compound of formula (11) has been carried out
    (eleven)
    With maleic acid, the next step in the process of obtaining the salt of formula (1) is to isolate said salt (step b)), that is, to separate the salt of formula (1) from the reaction medium.
    The isolation of the salt of formula (1) can be carried out by means of procedures common in the art such as centrifugation, filtration or combination of both.
    Optionally, the salt of formula (1) can be purified (step c)) using techniques
    10, for example, by washing with a solvent (in particular one or more washes, such as one, two or three washes), preferably with the solvent used in step a), by recrystallization or by combination of both techniques. In a particular embodiment, the salt of formula (1) is purified by one or more washes with the solvent used in step a).
    Silodosin preparation procedure
    In another aspect, the present invention relates to a method of preparing silodosin of formula (V)
    20 (VI
    which comprises hydrolyzing the salt of formula (1) to give the silodosin of formula (V).
    In a preferred embodiment, the salt of formula (1) is obtained by a process as defined above.
    Obtaining silodosin from said salt of formula (1) comprises the hydrolysis of the
    ester of benzoic acid to give the corresponding alcohol group and hydrolysis of the group
    nitrile to give the corresponding amido group and thus render silodosin. These
    hydrolysis can occur simultaneously or first the ester group can be hydrolyzed and
    5 then the nitrile group. Said hydrolysis of the ester and nitrile can be carried out in a
    same reactor (known reaction "one by ') or by stages in different reactors,
    preferably they are carried out in the same reactor.
    Hydrolysis of the ester group can be carried out by usual reaction conditions.
    1 o of hydrolysis of an ester to give the corresponding alcohol, which are known by the
    subject matter expert and are described, for example, in March's Advanced Organic Chemistry:
    Reactions, Mechanisms and Structure [Michael B. Smith and Jerry March, 6th edition, Wiley
    Interscience, John Wile & Son s, Inc. Hoboken, New Jersey, 2007]. In one embodiment
    particular said hydrolysis is carried out by treatment with a base such as a
    fifteen alkali metal hydroxide, for example sodium hydroxide or potassium hydroxide; a
    alkali metal carbonate, for example sodium carbonate, potassium carbonate or
    cesium carbonate Preferably the base used is an alkali metal hydroxide, more
    preferably sodium hydroxide. Said hydrolysis can also be performed by
    treatment with an acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid or
    twenty nitric acid.
    Hydrolysis of the nitrile group can be carried out by usual reaction conditions.
    of hydrolysis of a nitrile to give the corresponding amide, which are known by the
    subject matter expert and are described, for example, in March's Advanced Organic Chemistry:
    25 Reactions, Mechanisms and Structure [Michael B. Smith and Jerry March, 6th edition, Wiley
    Interscience, John Wile & Son s, Inc. Hoboken, New Jersey, 2007]. In one embodiment
    particular said hydrolysis is carried out by treatment with a base such as a
    alkali metal hydroxide, for example sodium hydroxide or potassium hydroxide; a
    alkali metal carbonate, for example sodium carbonate, potassium carbonate or
    30 cesium carbonate Preferably, the base used is an alkali metal hydroxide, more
    preferably sodium hydroxide. Said hydrolysis can also be performed by
    treatment with an acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid or
    nitric acid. Preferably hydrolysis of the nitrile group is carried out in the presence of a
    oxidizing agent, preferably hydrogen peroxide.
    35
    Therefore, in a particular embodiment, the hydrolysis of the salt of formula (1) to give silodosin is carried out in the presence of a base or an acid, as defined above, more preferably in the presence of a base, even more preferably in the presence of an alkali metal hydroxide, preferably sodium hydroxide. Saying
    The treatment allows hydrolyzing both the ester and nitrile of the salt of formula (1) in addition togenerate the salt free base.
    In a more preferred embodiment, the hydrolysis is further carried out in the presence of an oxidizing agent, such as hydrogen peroxide.
    A suitable solvent for carrying out the hydrolysis of the salt of formula (1) is dimethylsulfoxide. Therefore, in a particular embodiment dimethyl sulfoxide is used as the solvent.
    The hydrolysis is preferably carried out with stirring at a temperature between 20 oC and 60 oC, even more preferably between 30 oC and 50 oC, most preferably about 40 oC, preferably between 10 min and 60 min, more preferably between 10 min and 40 min, even more preferably between 15 min and 30 min
    The silodosin can be isolated from the reaction medium by standard procedures in the art, such as liquid-liquid extraction, centrifugation, filtration or combination thereof. For example, by liquid-liquid extraction and filtration.
    The silodosin obtained can be purified by washing, recrystallization or combination
    25 of both. For example by washing with toluene, recrystallization from toluene or isopropyl acetate, both washing and recrystallization from toluene or washing with toluene and recrystallization from isopropyl acetate. Different silodosin polymorphs can also be obtained, such as the beta polymorph and the silodosin gamma polymorph, polymorphs previously described in EP 1 541 55481.
    In a particular embodiment, the silodosin beta or gamma polymorphs have a D90 particle size of 200 µm to 800 µm.
    You can reduce the particle size of silodosin or any of its polymorphs,
    35 whose D90 is from 200¡Jm to 800¡Jm, by techniques known to those skilled in the art, such as grinding, micronization, crushing, or mixing of said techniques optionally accompanied by one or more screening operations. In particular, a reduction in particle size can be made by grinding and / or micronization.
    In a particular embodiment, the silodosin milled gamma polymorph is characterized by the following particle sizes: 090 = 45.5 IJm and / or 0 [4.3] = 20.1 IJm.
    In another particular embodiment, the silodosin micronized gamma polymorph is characterized by the following particle sizes: 090 = 12IJm and / or 0 [4,3] = 6, BlJm.
    In another particular embodiment, the silodosin milled beta polymorph is characterized by the following particle sizes: 090 = 73.7 IJm, Bear = 27.5 IJm and / or 0 [4.3] = 37.7 IJm.
    OX notation. which can also be written as O (v, O, X) means that the X% by volume of the particles have a smaller diameter than the specified diameter O. Therefore, 15 090 (or O (v, 0.9 »of 100 IJm means that 90% by volume of the particles have a diameter of less than 100 IJm.
    The notation 0 [4,3] refers to the mean particle diameter (by volume).
    20 The particle size can be determined by usual techniques known to the person skilled in the art, such as laser diffraction, in particular by a particle size analyzer Malvern model Mastersizer 2000 using the experimental protocol described in the corresponding section of materials and Methods of the examples.
    The following non-limiting examples are intended to illustrate the present invention and should not be construed as limitations on the scope of the present invention.
    Examples
    30 Materials and methods
    Magnetic resonance imaging (NMR):
    Bruker equipment, 300 MHz for 1H-RMN and 75.5 MHz for 13C_RMN. Deuterated Solvent
    It's CDCI. 35
    Infrared (IR) spectroscopy:
    Perkin Elmer FT-IR equipment with the ATR technique (direct measurement).
    HPLC-Mass Spectrometry (MS):
    Alliance-Waters 2695 system equipped with PDA detector and connected to a "single quadripole" 5 ionization equipment ESCi +/- micromass ZO.
    X-ray powder diffraction:
    The powder sample was placed between 3.6 micron thick polyester films. A PANalytical X'Pert PRO MPD 9/9 powder diffractometer of 540 mm radius or 10 240 mm radius was used in a convergent beam configuration with a focusing mirror and a transmission geometry with flat samples arranged between two low absorption films. Radiation Cu Ka (A = 1.5418 A). Working power: 45 kV -40 mA. Incident beam slits at a beam height of 0.4 mm. Soller slit of 0.02 incident and diffracted beam radians. PIXce / Detector: Active length = 3,347 0. Scans of 29/9 from 2 to
    15 40 ° 29 with a step of 0.026 ° 29 And a measurement time of 300 seconds per step (diffractometer of 540 mm radius), or alternatively scans of 29/9 from 5 to 30 ° 29 with a step of 0.026 ° 29 And a measurement time of 2000 seconds per step (diffractometer of 240 mm radius).
    20 Particle size: Instrumental conditions: Device: Malvern Mastersizer 2000 Accessory: Hydro 2000SM (A) Recirculation: 2,500 rpm
    25 Dispersant: Purified water, milli-O grade Sample preparation: In a watch glass, approximately 50 mg of sample is weighed, 3 to 5 drops of 0.2% Nonidet P40 (nonylphenylpolyethylene glycol) are added and mixed with a spatula to form a homogeneous paste trying to undo the agglomerates of product particles. The paste is transferred to a 50 mL glass with the
    30 help of 10 mL of water added with dropper trying to drag the maximum sample. The solution is left in an ultrasonic bath for 1 minute, during which time the alignment and the bottom of the equipment is performed by recirculating water through the circuit. Procedure: Without letting the sample stand and with the help of a dropper the amount of suspension to be studied is added, in the dispersion unit, to obtain a
    35 obscuration of approximately 15%. The reading is done after checking that the obscuration remains constant (approximately 10%). Ultrasound is not applied
    team interns.
    Micron crushing; Zation:
    5 In both cases an Alpine Hosokawa mill, Type M4-GMP, with a module 100 is used
    AFG To grind / micronize the silodosin, the working conditions of the Alpine Hosokawa mill are adjusted with the 100AFG module so that the particle size obtained is as desired.
    10 Comparative example 1. Formation of benzoate salts of 3- {7 -cyano-5 - [(2R) -2 - ({2- [2 (2.2.2-trifl uoroethoxy) phenoxy Mirta mi no) propi1) -2 3 -dih id ro-1 H-in dol-1-illpropi lo
    In a 500 mL reactor with mechanical agitation 50 9 of 5 - [(2R) -2aminopropyl) -1- [3- (bezoyloxy) propyl) -2,3-dihydro-1 H-indole-7-carbonitrile ( 2R, 3R) -2,3-di 15 hydroxybutanedioate (tartrate salt of the compound of formula (111), 26.9 9 K, CO "39.8 9 methanesulfonate 2- [2- (2,2, 2-Trifluoroethoxy) phenoxy] ethyl and 250 mL of acetonitrile, heated under reflux for 24 hours, after this time it is cooled to 20 oC and AcOEt (400 mL) and water (250 mL) is added, stirred for 30 min, and the phases are separated.The organic phase is dried with anhydrous sodium sulfate, filtered and concentrated to dryness, obtaining 70.9 9 of 20 benzoate 3- (7-cyano-5 - [(2R) -2- ({ 2- [2- (2,2,2-Trifluoroethoxy) phenoxy) eti I) amino) propyl) -2,3dihydro-1 H-indole-1-yl} propyl (free base). 18 9 of benzoate are weighed. 3- (7 -ciano-5 - [(2R} -2 ({2- [2 - (2, 2,2-trifluoroethoxy) phenoxy] eti I} amin o) propyl] -2, 3-d ih id ro -1 Hi ndol-1-yl} propyl and dissolved in 90 mL EtOH 96 °. 15 mL are distributed in different s balls. To each balloon a different acid (eg 0.60 g of maleic acid) dissolved in 15 mL 96 ° EtOH is added. Is left
    25 under stirring at room temperature for two hours and then cooled to 0-5 oC while maintaining stirring. In the case of maleic acid, after 30 min the maleate precipitates. If a salt forms, it is filtered, washed with EtOH 96 oC and dried in vacuo. Table 2 shows the result obtained with different acids. Table 2
    Acid Molar ratioSolventOutcome
    Maleic oneEtOHSolid
    Glycolic oneEtOHDissolution
    Citric Monohydrate oneEtOHDissolution
    Succinic oneEtOHDissolution
    Fumaric oneEtOHDissolution
    Hel in EtOH 2EtOHDissolution
    HBr 2EtOHDissolution
    H2S0 4 2EtOHDissolution
    H3P04 3EtOHDissolution
    Acetic 2EtOHDissolution
    Methanesulfonic 2EtOHDissolution
    Tartaric oneEtOHSolid
    Oxalic 1.02EtOHSolid
    The results in Table 2 show that only tartaric and oxalic acids (described in the state of the art) and maleic acid (present invention) yield the salt of
    3- (7-cyano-5- [(2 R) -2 - ((2- [2 - (2, 2-2-triflu oroethoxy) fe noxi) eti I} am i no) propi I) benzoate - - 2.3
    5 dihydro-1 H-indol-1-yl} propyl in solid form and therefore suitable for separating from the dialkylated impurity in the method of obtaining silodosin.
    Example 2. Synthesis of 3- {7-cyano-5 - [(2R) -2 - ({2- [2 (2 2 2-trifluoroethoxy) phenoxyJetinamino) propyl J-2 3-dihydro malezoic acid salt -1 H-indole-1 -propyl of formula (1)
    ! OH O (1) ACN, K, CO, (2) H, O (3) IPA / maleic acid
    O o
    5 - [(2R) -2-aminopropyl) -1- [3- (bezoyloxy) propyl) -2,3-dihydro-1 H-indole were charged 7-Carbonitrile (2R, 3R) -2,3-dichydroxybutanedioate (tartrate salt of the compound of formula
    (111); 1 kg), 2- (2- (2,2,2-trifluoroethoxy) phenoxy] ethyl methanesulfonate (0.7 kg) and potassium carbonate (0.5 kg) Acetonitrile (ACN, 5 L) was charged in the reactor under nitrogen atmosphere, then the reactor contents were mixed and heated under reflux under nitrogen atmosphere, the mixture was refluxed for 24 hours, then the reactor was cooled to 50 ° C and water was charged (3 L) in the reactor The reactor contents were cooled and kept at 20 ° C for 15 min.The phases were allowed to separate, the aqueous phase was removed and the remaining content was distilled under reduced pressure at 70 ° C. isopropanol (IPA, 5 L) in the reactor and a solution of maleic acid (0.25 kg) in isopropanol (5 L) The reaction mixture was heated to 50 ° C and maintained at this temperature until complete dissolution. The reactor contents were cooled and kept at 20 ° C for at least 15 hours.The suspension obtained was centrifuged, washed with isopropanol (3 L) Y It was allowed to drain for 3 h. Then, the product obtained was dried under vacuum for 2 h at room temperature and for approximately 5 h at 35 oC. The powder X-ray diffractogram of the solid obtained is shown in Figure 1 and the peaks are listed in Table 1 (described
    15 above).
    'H-NMR (CDCI "300 MHz): OR 1.37 (d, J = 6.6 Hz, 3H), 2.13 (qn, J = 6.6 Hz, 2H), 2.69 (dd, J = 9.0, 13.8 Hz, 1H), 2.93 (1, J = 8.7 Hz, 2H), 3.10 (dd, J = 5.1, 13.5 Hz, 1H), 3.40-3.60 (m, 5H), 3.73 (1, J = 7.2 Hz, 2H), 4.37 (1, J = 3.9 Hz, 2H), 4.38 (q , J = 8.4 Hz, 2H), 4.44 (1, J = 6.5 Hz,
    20 2H), 6.22 (s, 2H), 6.80-7.00 (m, 6H), 7.43 (1, J = 7.5 Hz, 2H), 7.56 (tt, J = 1.6, 7.65 Hz, 1 H), 8.05 (d, J = 8.4 Hz, 2H) ppm. "C-NMR (CDCI" 75, S MHz): OR 15.4, 27.0, 27.1, 38, S, 43.9, 45.0, 53.2, 55.6, 62.4, 65.0, 67.3, 87.7, 115.3, 116.4, 119.1, 122.6, 123.4, 123.9, 124.2, 128.3, 129.4, 129, 6, 130.0, 132.0, 132.9, 133.2, 135.8, 147.4, 148.0, 152.0, 166.7, 169.8 ppm. MS (miz): 582.8 [M + 1r. IR: v (cm "): 2200, 1717.
    Example 3. Synthesis of the silodosin gamma polymorph
    ° °
    (one) DMSO; NaOH / H, O,
    (2) Na, S0 3; NaCl; Toluene
    (3) H, O / toluene
    !
    °
    ~ OH
    CCO ~ I N
    ¿; O / "'o-.CF H 3
    The salt of the maleic acid of 3- {7 -cyano-5 - [(2R) -2 - ({2 [2- (2,2,2-trifluoroethoxy) phenoxy] ethyl} amino) benzoate was charged into a reactor propyl] -2,3-dihydro-1 H-indol-1-yl} propyl of formula (1) obtained in example 2 (1 kg) and dimethylsulfoxide (DMSO, 6 L) And the mixture was stirred. A solution of 5 N sodium hydroxide (1.4 L) was then added. 33% hydrogen peroxide (1.8 L) was added slowly maintaining the temperature at approximately 40 ° C and the reactor mixture was maintained at 40 ° C for 15-30 min under stirring. Next, a 5% aqueous solution of sodium sulphite (1.9 L) was added to the reactor contents and with stirring. A saturated aqueous solution of sodium chloride (8 L) was charged onto the same reactor. Then, toluene (10 L) was added and the reactor content was heated at 70 ° C for at least 15 min. Stirring was stopped, the phases were allowed to separate and the aqueous phase was removed. The reactor contents were cooled and stirred for at least 2 h at 25 ° C. The suspension was centrifuged and allowed to drain, washed with toluene (5 L) and allowed to drain again. X-ray powder diffractogram
    15 of the silodosin gamma polymorph is shown in Figure 2.
    Example 4. Synthesis of the silodosin gamma polymorph
    Silodosin reactor obtained in example 3 (1 kg), water (5 L) and toluene were loaded into a reactor
    20 (18 L) Y was stirred at 65 oC. The mixture was allowed to decant and the aqueous phase was removed. The mixture was stirred and heated at 65 ° C until complete dissolution. The solution was cooled to 50 ° C and seeded with silodosin gamma form. The reactor contents were cooled and the suspension was stirred at 25 ° C for at least 2 h. The suspension was centrifuged, washed with toluene and allowed to drain. The X-ray powder diffractogram of the silodosin gamma polymorph is shown in Figure 2. The obtained polymorph gamma silodosin has a 090 of 200¡1m
    5 to 800 ... 1m. Then, the solid obtained is ground and micronized to obtainGamma polymorph silodosin with the following particle sizes:- Silodosin milled gamma polymorph 090 = 45.5¡1m and D (4.3] = 20.1¡1m;- Micronized gamma polymorph of silodosin D90 = 12¡1m and 0 (4.3] = 6.8¡1m.
    10 Example 5. Synthesis of the silodosin beta polymorph
    Silodosin reactor obtained in example 4 (1 kg) and isopropyl acetate (15 L) were loaded into a reactor. The mixture was stirred and heated at 70-75 ° C until completely dissolved. It was cooled to 50 oC and seeded with silodosin beta form. It was stirred at 50 ° C for 30 min. It was gradually cooled 15 to O-5 ° C and maintained at this temperature for 1 h. The product was centrifuged and washed with isopropyl acetate (5 L). It was dried at 75 ° C under vacuum for 4 h. The powder X-ray diffractogram of the silodosin beta polymorph obtained is shown in Figure 3. The obtained beta polymorph silodosin has a D90 of 200 J.lm to 800 J.lm. Then, the solid obtained is milled obtaining silodosin polymorph beta with the following sizes of
    20 particle: 090 = 73.7 ~ m, Bear = 27, S ~ m, 0 (4.3] = 37.7 ~ m.
    Example 6. Silodosin formulations
    Ingredients of the formulations (the amounts are expressed in% w / w):
    25 Silodosin (beta or gamma): 2.3% Mannitol: 80.7% Pregelatinized starch 1500: 15.0% Sodium lauryl sulfate: 1.0% Magnesium sterarate: 1.0%
    The silodosin formulations were prepared by simple mixing of the components, first the silodosin (using the particle sizes and polymorphs described in examples 4 and 5) with the mannitol and subsequently with the rest of the formulation ingredients. Finally it was encapsulated and introduced in PVC-PVDC blisters 90 g / m2
    35 (polyvinyl chloride-polyvinylidene chloride). One part was introduced in HOPE bottles
    (high density polyethylene).
    权利要求:
    Claims (15)
    [1]

    one. Maleic acid salt of formula (1)
    OROR
    HO- {J-OH
    5 (one).
    [2]
    2. Salt of formula (1) according to claim 1 in crystalline form characterized in that its
    X-ray powder diffractogram (registered with an x-ray source of copper)
    it presents peaks at 11, 9, 14.6, 15.4, 17.1, 18.4, 21, 0, 23.4 and 23.9 '28 ± 0.2' 28.
    10
    [3]
    3. Salt according to claim 2, characterized in that its X-ray diffractogram of
    powder also has peaks at 11, 7, 14.4, 16.7 and 18.9 '28 ± 0.2' 28.
    [4]
    Four. Process for the preparation of the salt of formula (1) defined in claim 1,
    fifteen which includes:
    to) treat the compound of formula (11)
    (eleven)
    with maleic acid; Y
    twenty b)isolate the salt of formula (1).
    [5]
    5. Processaccordingtheclaim4,inwherethestageto)bemakesina
    solvent selected from group consistinginisopropanol, methanol, ethanol, n
    Propanol, tert-butanol and n-butanol.
    25
    [6]
    Method according to any one of claims 4 or 5, which previously comprises the treatment of a compound of formula (111) or a salt thereof
    in
    or
    (111)
    5 with a compound of formula (IV)
    wherein GS is a leaving group, in an aprotic polar solvent and in the presence of a base, to give the compound of formula (11).
    [7]
    7. Process according to claim 6, wherein the salt of the tartaric acid of the compound of formula (111) is treated.
    Method according to claim 7, wherein the salt of the tartaric acid is a salt of the acid (2R, 3R) - (+) - tartaric acid.
    [9]
    9. The method according to any of claims 6 to 8, wherein the leaving group GS of the compound of formula (IV) is selected from the group consisting of
    20 methanesulfonyloxy, toluenesulfonyloxy and trifluoromethanesulfonyloxy, preferably methanesulfonyloxy.
    [10]
    10. Process according to any of claims 6 to 9, wherein the aprotic polar solvent is acetonitrile.
    [11]
    eleven. Process according to any of claims 6 to 10, wherein the base is potassium carbonate.
    [12]
    12. Preparation procedure of silodosin of formula (V)

    NH,
    í '- OH N
    (V)
    which comprises hydrolyzing the salt of formula (1) to give the silodosin of formula (V).
    13. Method according to claim 12, wherein the salt of formula (1) is obtainedby the method defined in any of claims 4 to 11.
    [14]
    14. Method according to any of claims 12 or 13, wherein the hydrolysis
    It is performed in the presence of an alkali metal hydroxide. 10
    [15]
    15. Process according to claim 14, wherein the alkali metal hydroxide is sodium hydroxide.
    [16]
    16. Process according to any of claims 12 to 15, wherein the hydrolysis is carried out in the presence of an oxidizing agent.
    [17]
    17. Process according to claim 16, wherein the oxidizing agent is hydrogen peroxide.
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2602123T3|2017-02-17|Preparation of neratinib maleate salt
    ES2617680T3|2017-06-19|Process for the preparation of pyrrolidinium salts
    JP2018522012A|2018-08-09|Prepare N- | -N- | -N ′-| phenylmethyl) carbamide and its tartrate salt and polymorph Form C how to
    ES2647949T3|2017-12-27|Process for enhanced opioid synthesis
    JP4763594B2|2011-08-31|A novel polymorph of olanzapine hydrochloride
    ES2607639A1|2017-04-03|Maleic acid salt of a silodosin intermediate |
    WO2010139979A2|2010-12-09|Processes for preparing crystalline forms
    US20210371397A1|2021-12-02|Synthesis of omecamtiv mecarbil
    CA2871453A1|2013-10-31|Quinazolinedione derivative
    ES2769255T3|2020-06-25|Methods for making protein deacetylase inhibitors
    JP6081450B2|2017-02-15|Crystalline salt of asenapine
    CA2916329A1|2015-01-08|Crystalline forms of ponatinib hydrochloride
    ES2837084T3|2021-06-29|Calcium salts are sacubitril
    ES2585287T3|2016-10-04|Pyrazolopyrimidine derivative
    JP6770962B2|2020-10-21|Method for producing thiazole derivative
    WO2015119057A1|2015-08-13|Method for producing indoline compound
    JP2018516946A|2018-06-28|Crystal forms of histone deacetylation inhibitors
    EP2004655A1|2008-12-24|Polymorphic forms of |-2-amino-2-cyclohexyl-n-|-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
    JP2021510149A|2021-04-15|New crystalline form of acarabrutinib and its manufacturing method and application
    AU2019290545A1|2020-11-19|Solid forms of 3-|-1-|azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
    ES2618178T3|2017-06-21|Ester salts | - 2- | -propyl] -methyl-amino} -ethyl) - Isobutyric acid 5-phenyl-bicyclo [2.2.2] oct-5-en-2-yl
    ES2590027T3|2016-11-17|Method for preparing fesoterodine fumarate
    KR20200024302A|2020-03-06|Salts, Polymorphs, and Pharmaceutical Compositions and Uses of Phenylpyrimidone Compounds
    WO2020151756A1|2020-07-30|Stable solid dispersions of b-raf kinase dimer inhibitor, methods of preparation, and uses therefor
    ES2822398A1|2021-04-30|3 - | -2- | -1- | -5-iodo-6-methyl-1H-pyrimidine-2,4-dione or a salt of the same, procedure for its preparation and its use in the synthesis of elagolix |
    同族专利:
    公开号 | 公开日
    US20180265469A1|2018-09-20|
    US10421719B2|2019-09-24|
    WO2017055664A1|2017-04-06|
    ES2607639B1|2018-02-28|
    JP2018530556A|2018-10-18|
    EP3357907A4|2018-08-15|
    CA3000580A1|2017-04-06|
    KR20180095795A|2018-08-28|
    JP6877415B2|2021-05-26|
    EP3357907A1|2018-08-08|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP1806340A1|2004-10-27|2007-07-11|Kissei Pharmaceutical Co., Ltd.|Indoline compound and process for producing the same|
    WO2012131710A2|2011-03-30|2012-10-04|Panacea Biotec Ltd|Novel process for the synthesis of indoline derivatives|
    CN102382029A|2011-07-26|2012-03-21|浙江华海药业股份有限公司|Preparation method of salt formation of silodosin intermediate|
    WO2013056852A1|2011-10-21|2013-04-25|Noxxon Pharma Ag|Glucagon binding nucleic acids|
    WO2015015512A2|2013-07-29|2015-02-05|Ind-Swift Laboratories Limited|Process for the preparation of silodosin and its gamma form|
    WO2015085827A1|2013-12-09|2015-06-18|上海科胜药物研发有限公司|Method for preparing silodosin and intermediate thereof|
    DE122010000031I1|1992-12-02|2010-10-21|Kissei Pharmaceutical|Indoline compounds for the treatment of dysuria|
    JP3331048B2|1994-06-01|2002-10-07|キッセイ薬品工業株式会社|Indole derivatives|
    HU0100680A3|1998-02-27|2001-09-28|Kissei Pharmaceutical|Indole derivatives and medicinal compositions containing the same|
    JP4634560B2|2000-01-14|2011-02-23|キッセイ薬品工業株式会社|Process for producing optically active indoline derivative and production intermediate thereof|
    JP4921646B2|2001-03-08|2012-04-25|キッセイ薬品工業株式会社|1- -5- indoline derivatives and methods of use thereof|
    AU2003264385B2|2002-09-06|2009-12-17|Kissei Pharmaceutical Co., Ltd.|Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same|
    JP2006188470A|2005-01-07|2006-07-20|Kissei Pharmaceut Co Ltd|Indoline derivative and method for producing the same|
    EP2125717B1|2007-02-26|2013-07-03|Concert Pharmaceuticals Inc.|Deuterated derivatives of silodosin as alpha ia-adrenoreceptor antagonists|
    CN101585798B|2008-05-20|2011-06-15|浙江华海药业股份有限公司|Optical active compound of 1--5- propyl-7-cyano indoline as well as preparation method and application thereof|
    CN101302183B|2008-07-01|2010-09-29|中国药科大学|Preparation of 5-substituted-1--7-carbamyl indoline|
    CN101412690A|2008-12-01|2009-04-22|巢杰|Medicinal acid addition salt of silodosin, and preparation and medicament use thereof|
    CN101993406B|2009-08-27|2014-01-15|浙江华海药业股份有限公司|Indoline compound with optical activity and preparation method thereof|
    CN101993405B|2009-08-27|2014-01-15|浙江华海药业股份有限公司|Indoline derivative as well as preparation method and application thereof|
    CN101993407B|2009-08-27|2014-01-29|浙江华海药业股份有限公司|Indoline compound for preparing silodosin and preparation method thereof|
    CA2772997A1|2009-09-12|2011-03-17|Sandoz Ag|Process for the preparation of indoline derivatives and their intermediates thereof|
    CN101759627A|2009-09-15|2010-06-30|傅军|Novel preparation method of silodosin|
    CN102115455A|2009-12-30|2011-07-06|北京德众万全药物技术开发有限公司|Method for preparing psilocine key intermediate|
    WO2011101864A1|2010-02-17|2011-08-25|Panacea Biotec Ltd|Novel process for the synthesis of phenoxyethyl derivatives|
    WO2011124704A1|2010-04-09|2011-10-13|Ratiopharm Gmbh|Process for preparing an intermediate for silodosin|
    CN102311319A|2010-07-05|2012-01-11|浙江华海药业股份有限公司|Method for preparing 2- anisole|
    WO2012014186A1|2010-07-30|2012-02-02|Ranbaxy Laboratories Limited|Process for the preparation of silodosin and its novel intermediates|
    WO2012062229A1|2010-11-12|2012-05-18|Zentiva, K.S.|A method of manufacturing -l--5-[-2-- phenoxyethyl}amino)propyl]-2,3-dihydro-lh-indole-7-carboxamide|
    SG11201403769YA|2012-01-10|2014-07-30|Noxxon Pharma Ag|Nucleic acids specifically binding cgrp|
    CN102643221B|2011-02-22|2015-02-11|浙江九洲药业股份有限公司|Silodosin intermediate and preparation method thereof|
    WO2012147019A1|2011-04-26|2012-11-01|Orchid Chemicals And Pharamceuticals Limited|An improved process for the preparation of silodosin|
    WO2012147107A2|2011-04-29|2012-11-01|Msn Laboratories Limited|Novel & improved processes for the preparation of indoline derivatives and its pharmaceutical composition|
    CN102320996A|2011-07-14|2012-01-18|四川大学|A kind of preparation of silodosin midbody and purification process|
    WO2013072935A2|2011-10-10|2013-05-23|Cadila Healthcare Limited|Process for the preparation of silodosin|
    CN104302621A|2011-10-21|2015-01-21|桑多斯股份公司|Method for preparing silodosin|
    CN102690223A|2012-05-24|2012-09-26|临海天宇药业有限公司|Preparation method for 1-acetyl-7-cyanopyridine-5- indoline|
    CN102702067B|2012-06-18|2015-01-14|北京联本医药化学技术有限公司|Novel intermediate for synthesizing silodosin as well as preparation method and purpose of novel intermediate|
    CN102746210A|2012-07-20|2012-10-24|江苏宇田生物医药科技有限公司|Synthesis method for key intermediate of silodosin|
    WO2014060571A1|2012-10-18|2014-04-24|Sandoz Ag|A process for preparing indoline derivatives|
    CN103848772A|2012-11-30|2014-06-11|苏州四同医药科技有限公司|Preparation method of important intermediate of Silodosin|
    WO2014118606A2|2013-01-29|2014-08-07|Alembic Pharmaceuticals Limited|A novel process for the preparation of silodosin|
    EP2961730A2|2013-02-26|2016-01-06|XenoPort, Inc.|Method of making 1--alkyl carbamate compounds|
    US9862681B2|2013-04-09|2018-01-09|Mankind Research Centre|N-haloalkylindoline intermediates, their process and use in preparation of Silodosin and its derivatives|
    CN104140389A|2013-05-06|2014-11-12|昆明积大制药股份有限公司|Preparing method of silodosin and intermediate thereof|
    CN103265470B|2013-05-29|2015-10-28|华润赛科药业有限责任公司|A kind of synthetic method of silodosin dialkylate|
    CN104230782A|2013-06-09|2014-12-24|昆明积大制药股份有限公司|Synthetic method of silodosin|
    CN103420893B|2013-08-02|2015-11-25|江苏和成新材料有限公司|Prepare the method for Silodosin intermediate|
    CN103554003B|2013-11-18|2016-06-22|连云港贵科药业有限公司|A kind of synthetic method of silodosin|
    KR101447574B1|2013-11-29|2014-10-07|동국제약 주식회사|Method for preparing silodosin using new intermediates|
    KR102114323B1|2013-12-09|2020-05-22|이니스트에스티 주식회사|Method of preparing 1-propan-2-ol derivatives|
    KR20150066777A|2013-12-09|2015-06-17|동우신테크 주식회사|Indoline derivatives and method of preparing the same|
    CN104744336B|2013-12-26|2017-07-14|安徽省庆云医药股份有限公司|A kind of Silodosin intermediate and preparation method thereof, and the method for preparing with the intermediate silodosin|
    WO2015119057A1|2014-02-06|2015-08-13|宇部興産株式会社|Method for producing indoline compound|
    IN2014MU00483A|2014-02-11|2015-11-13|
    JP2015151395A|2014-02-14|2015-08-24|ディフアルマ フランチス ソシエタ ア レスポンサビリタ リミタータＤｉｐｈａｒｍａ Ｆｒａｎｃｉｓ Ｓ．Ｒ．Ｌ．|Method of preparing adrenergic antagonist|
    KR20150098478A|2014-02-20|2015-08-28|주식회사 종근당|Novel method for preparing crystal form γ of silodosin|
    KR20150098565A|2014-02-20|2015-08-28|한미정밀화학주식회사|Novel intermediate used for the preparation of silodosin, method for preparing same, and method for preparing silodosin using same|
    JP6893598B2|2014-03-14|2021-06-23|バイオモレキュラー・ホールディングス・エルエルシーＢｉｏｍｏｌｅｃｕｌａｒ Ｈｏｌｄｉｎｇｓ ＬＬＣ|Hybrid immunoglobulin containing non-peptidyl binding|
    CN104974072B|2014-04-10|2017-11-03|江苏和成新材料有限公司|A kind of method for preparing Silodosin intermediate|
    CN104974073B|2014-04-10|2017-11-03|江苏和成新材料有限公司|A kind of method for preparing Silodosin intermediate|
    JP6242298B2|2014-06-13|2017-12-06|株式会社トクヤマ|1- -7-cyano-5-[ -2- phenoxy] ethyl} amino) propyl] indoline Or a method for producing the salt thereof|
    KR101628946B1|2014-07-09|2016-06-09|동방에프티엘|Improved Process of Silodosin|
    KR101725393B1|2014-07-24|2017-04-27|주식회사 경보제약|Manufacturing method for Silodosin and new intermediate thereof|
    KR101744046B1|2014-09-01|2017-06-08|다산메디켐|Process for preparing an intermediate useful for the synthesis of silodosin|
    KR101725061B1|2014-09-01|2017-04-27|다산메디켐|Process for preparing silodosin|
    WO2016042441A1|2014-09-18|2016-03-24|Mankind Research Centre|A novel process for the preparation of considerably pure silodosin|
    JP2016064988A|2014-09-22|2016-04-28|株式会社トクヤマ|Method for manufacturing tartrate of 1--7-cyano-5-[-2-phenoxy]ethyl}amino)propyl]indoline|
    JP2016088847A|2014-10-30|2016-05-23|株式会社トクヤマ|Method for producing -1--5-[[-2-phenoxy]ethyl}amino)propyl]-2,3-dihydro-1h-indole-7-carboxamide])|
    KR101694262B1|2014-12-18|2017-01-10|다산메디켐|Process for preparing crystalline forms of silodosin|
    CN104557662B|2014-12-26|2017-01-25|华润赛科药业有限责任公司|Synthesis method of silodosin dialkyl compound|
    WO2016139773A1|2015-03-04|2016-09-09|株式会社三洋化学研究所|Novel synthesis method for silodosin synthetic intermediate|
    KR101686087B1|2015-03-09|2016-12-15|제이투에이치바이오텍 |Process for Production of Optically Active Indoline Derivatives or Salts Thereof|
    KR20160109736A|2015-03-13|2016-09-21|주식회사 한서켐|Process for preparing intermediate of silodosin|
    WO2016189552A2|2015-05-26|2016-12-01|Ipca Laboratories Limited|Novel recovery and recycling process of unwanted enantiomers of 2-aminopropyl indoline derivatives|
    JP2018528233A|2015-09-23|2018-09-27|バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ|Process for producing indoline compounds and novel indoline salts|
    CN105254553B|2015-11-09|2018-04-10|黄欢|The preparation method of Silodosin intermediate|
    CN106995399A|2016-01-25|2017-08-01|北京天泰恒华医药技术有限公司|A kind of method for preparing Silodosin|
    CN106045892B|2016-05-27|2019-05-28|齐鲁制药有限公司|The new preparation process of Silodosin and its intermediate|
    CN106083689B|2016-06-14|2020-07-31|齐鲁制药有限公司|Preparation method of silodosin compound|
    CN106045895B|2016-06-18|2018-09-04|浙江天宇药业股份有限公司|A kind of preparation method of Silodosin intermediate|
    CN106496092B|2016-08-30|2019-03-29|江苏宇田医药有限公司|It is a kind of for synthesizing the preparation method of the intermediate of silodosin|
    CN106380438B|2016-08-30|2019-07-30|江苏宇田医药有限公司|It is a kind of for synthesizing the preparation method of the indoline derivative object of silodosin|CN107056675B|2017-05-10|2019-09-03|浙江天宇药业股份有限公司|A kind of synthetic method of silodosin and its intermediate|
    EP3354283B1|2017-06-20|2019-08-07|Alfred E. Tiefenbacher |Pharmaceutical capsule composition comprising silodosin|
    WO2020237645A1|2019-05-31|2020-12-03|上海汇伦生命科技有限公司|Preparation method for silodosin intermediate|
    法律状态:
    2018-02-28| FG2A| Definitive protection|Ref document number: 2607639 Country of ref document: ES Kind code of ref document: B1 Effective date: 20180228 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201531398A|ES2607639B1|2015-09-30|2015-09-30|Maleic acid salt of a silodosin intermediate|ES201531398A| ES2607639B1|2015-09-30|2015-09-30|Maleic acid salt of a silodosin intermediate|
    EP16850424.9A| EP3357907A4|2015-09-30|2016-09-29|Maleic acid salt of a silodosin intermediate|
    US15/763,689| US10421719B2|2015-09-30|2016-09-29|Maleic acid salt of a silodosin intermediate|
    PCT/ES2016/070682| WO2017055664A1|2015-09-30|2016-09-29|Maleic acid salt of a silodosin intermediate|
    CA3000580A| CA3000580A1|2015-09-30|2016-09-29|Maleic acid salt of a silodosin intermediate|
    JP2018517287A| JP6877415B2|2015-09-30|2016-09-29|Maleate of silodosin intermediate|
    KR1020187012164A| KR20180095795A|2015-09-30|2016-09-29|The maleic acid salt of the gum arabic intermediate|
    [返回顶部]